Trial · NCT05667402
Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia
NCT05667402, Not applicable, Unknown, First Affiliated Hospital Xi'an Jiaotong University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia. Trials, record NCT05667402. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05667402
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia
- NCT number
- NCT05667402
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- First Affiliated Hospital Xi'an Jiaotong University
- Conditions
- Central Nervous System Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation
- Interventions
- TBF regimen, modified BuCY2 regimen
- First posted
- 2022-12-28
- Last updated
- 2022-12-28
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recurrence rate of central nervous system (CNS) leukemia | From date of the treatment with the conditioning regimen until CNS leukemia relapse, the end of follow-up or the date of death from any cause, whichever came first, assessed up to 36 months. | The proportion of patients with recurrent central nervous system leukemia in the total enrolled population |
| Secondary | Hematopoietic implantation rate | From date of the treatment with the conditioning regimen until hematopoietic implantation, assessed up to 100 days.. | Hematopoiesis was achieved within 100 days after allo-HSCT |
| Secondary | NRM | From date of allo-HSCT until the date of death from any cause or the end of follow-up, whichever came first, assessed up to 36 months. | non-recurrence mortality |
| Secondary | OS | From date of the treatment with the conditioning regimen until the end of follow-up or the date of death from any cause, whichever came first, assessed up to 36 months. | overall survival |
| Secondary | PFS | From date of the treatment with the conditioning regimen until leukemia progression, the end of follow-up or the date of death from any cause, whichever came first, assessed up to 36 months. | progression-free survival |
| Secondary | AEs | From date of the treatment with the conditioning regimen until the occurrence of adverse effects, the end of follow-up or the date of death from any cause, whichever came first, assessed up to 36 months. | adverse effects |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05667402
GET https://conductscience.org/api/trials/v1/NCT05667402/registered